Supernus Pharmaceuticals, INC Form 4 insider transactions

Jack A. Khattar, President, CEO and a Director of Supernus Pharmaceuticals, Inc., reported multiple transactions in common stock on August 12, 2026.

Jonathan Rubin, SVP, Chief Medical Officer of Supernus Pharmaceuticals, Inc., reported multiple transactions in common stock on August 12, 2026.

Timothy C Dec, Senior Vice-President & CFO of Supernus Pharmaceuticals, Inc., reported multiple transactions in common stock on August 12, 2026.

Indivior and Supernus Pharmaceuticals announce an all-stock merger of equals to create a leading U.S. biopharmaceutical company focused on central nervous system diseases.

Supernus Pharmaceuticals and Indivior Pharmaceuticals announced an all-stock merger of equals to create a leading U.S. biopharma company focused on central nervous system (CNS) diseases.

Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a merger of equals to create a diversified CNS biopharmaceutical leader with significant scale and an expanded portfolio of 11 medicines.

Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a merger of equals, creating a diversified CNS biopharmaceutical company with expected annual cost synergies of $125 million.

Jack A. Khattar, President, CEO and a Director of Supernus Pharmaceuticals, Inc., received 29,849 shares of common stock on July 29, 2026.

Timothy C Dec, Senior Vice-President & CFO of Supernus Pharmaceuticals, Inc., received 1,250 shares of common stock on July 29, 2026.

Frank Mottola, SVP, Chief Tech. Ops. Officer of Supernus Pharmaceuticals, Inc., received 1,650 shares of common stock on July 29, 2026.

Padmanabh P. Bhatt, Sr. VP of IP, CSO of Supernus Pharmaceuticals, Inc., received 2,500 shares of common stock on July 29, 2026.

Jonathan Rubin, SVP, Chief Medical Officer of Supernus Pharmaceuticals, Inc., received 750 shares of common stock on July 29, 2026.

Supernus Pharmaceuticals CEO Jack Khattar reported the sale of 35,000 shares of common stock from a trust under a pre-arranged 10b5-1 trading plan.

Supernus Pharmaceuticals Director Frederick M. Hudson sold 5,369 shares of common stock at a weighted average price of $50.61 per share under a pre-arranged trading plan.

Supernus Pharmaceuticals' Senior Vice-President and CFO, Timothy C. Dec, acquired 3,000 performance share units, which vested upon achievement of performance objectives.

Supernus Pharmaceuticals' SVP, Chief Technology Operations Officer, Frank Mottola, reported the vesting of restricted stock units and subsequent tax-related share disposition.

Supernus Pharmaceuticals CFO Timothy Dec reported the vesting of 2,500 restricted stock units and a subsequent sale of shares for tax purposes.

Supernus Pharmaceuticals' Sr. VP of IP, CSO, Padmanabh P. Bhatt, reported the vesting of 1,250 restricted stock units and the subsequent sale of 650 shares for tax obligations.

Supernus Pharmaceuticals' Chief Medical Officer, Jonathan Rubin, reported the acquisition of shares from restricted stock unit vesting and subsequent sale for tax obligations.

Supernus Pharmaceuticals CFO Timothy C. Dec reported the vesting of restricted stock units and the subsequent disposition of shares to cover tax obligations.

Supernus Pharmaceuticals Director Charles W. Newhall III converted 4,475 restricted stock units into common stock.

Supernus Pharmaceuticals Director Frederick M. Hudson converted 4,475 restricted stock units into common stock, increasing his direct beneficial ownership.

Supernus Pharmaceuticals Director Carrolee Barlow converted 4,475 restricted stock units into common stock, increasing her direct beneficial ownership.

A Supernus Pharmaceuticals executive reported the vesting of Restricted Stock Units and subsequent share transactions for tax purposes.

Supernus Pharmaceuticals SVP Frank Mottola reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Supernus Pharmaceuticals' SVP, Chief Medical Officer Jonathan Rubin reported changes in his beneficial ownership of common stock and restricted stock units.

Supernus Pharmaceuticals Director Georges Gemayel increased his beneficial ownership by acquiring 19,475 shares through option exercise and restricted stock unit vesting.

Supernus Pharmaceuticals Director Bethany Sensenig sold 4,475 common stock shares on February 19, 2026, following the vesting of restricted stock units.

Supernus Pharmaceuticals Director Frederick M. Hudson exercised options to acquire 15,000 shares of common stock.

A Supernus Pharmaceuticals executive exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged trading plan.